Nov 14, 2025 04:44PM XenoTherapeutics to acquire Repare Therapeutics for $1.82 per share

Oct 28, 2025 06:42AM Repare Therapeutics (RPTX) PT Lowered to $3 at H.C. Wainwright

Aug 8, 2025 09:39AM Repare Therapeutics Inc. (RPTX) Tops Q2 EPS by 17c

Jul 15, 2025 04:06PM Repare Therapeutics licenses cancer drug lunresertib to Debiopharm

May 13, 2025 04:15PM Repare Therapeutics Inc. (RPTX) Misses Q1 EPS by 8c

Mar 31, 2025 04:39PM Repare Therapeutics (RPTX) Announces Leadership Transitions

Mar 7, 2025 06:40AM Repare Therapeutics (RPTX) PT Lowered to $5 at H.C. Wainwright

Mar 3, 2025 07:44AM Repare Therapeutics Inc. (RPTX) Tops Q4 EPS by 14c

Mar 3, 2025 07:05AM Repare Therapeutics Inc. (RPTX) Provides Business and Clinical Update

Jan 10, 2025 12:44PM Repare Therapeutics (RPTX) PT Lowered to $3 at Stifel

Jan 10, 2025 09:02AM Bloom Burton & Co. Downgrades Repare Therapeutics (RPTX) to Hold (3)

Dec 13, 2024 09:24AM Repare Therapeutics (RPTX) PT Lowered to $4 at Stifel; 'Removing PROC Lowers TP'

Dec 12, 2024 04:22PM Repare Therapeutics (RPTX) Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

Nov 12, 2024 07:08AM Repare Therapeutics Inc. (RPTX) Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib

Nov 7, 2024 08:10AM Repare Therapeutics Inc. (RPTX) Tops Q3 EPS by 6c

Oct 23, 2024 12:55PM Stifel Reiterates Buy Rating on Repare Therapeutics (RPTX)

Oct 23, 2024 06:07AM Repare Therapeutics Inc. (RPTX) Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial

Oct 14, 2024 07:09AM Repare Therapeutics Inc. (RPTX) Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor

Oct 1, 2024 07:28AM Piper Sandler Reiterates Overweight Rating on Repare Therapeutics (RPTX)

Oct 1, 2024 06:53AM Stifel Reiterates Buy Rating on Repare Therapeutics (RPTX)

Sep 30, 2024 04:07PM Repare Therapeutics (RPTX) Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment

Sep 23, 2024 07:08AM Repare Therapeutics (RPTX) Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers

Sep 23, 2024 06:39AM H.C. Wainwright Reiterates Buy Rating on Repare Therapeutics (RPTX)

Sep 16, 2024 07:39AM Piper Sandler Reiterates Overweight Rating on Repare Therapeutics (RPTX)

Sep 4, 2024 07:28AM H.C. Wainwright Reiterates Buy Rating on Repare Therapeutics (RPTX)

Aug 6, 2024 06:08PM Repare Therapeutics Inc. (RPTX) Tops Q2 EPS by 5c

Jun 27, 2024 12:38PM TD Cowen Reiterates Buy Rating on Repare Therapeutics (RPTX)

Jun 27, 2024 07:17AM Repare Therapeutics (RPTX) PT Lowered to $9 at Stifel

Jun 26, 2024 10:30AM Repare Therapeutics Inc. (RPTX) Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial

Jun 10, 2024 06:09AM Repare Therapeutics (RPTX) Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial